Thousand Oaks, CA, and Ingelheim, Germany (Press Release) – Amgen (NASDAQ: AMGN) and Boehringer Ingelheim today announced that Amgen has acquired global devel­op­ment and commercial rights from Boehringer Ingelheim for BI 836908 (AMG 420), a bispecific T cell engager (BiTE®) that targets B-cell maturation an­ti­gen (BCMA), a poten­tial target for multiple myeloma. BI 836908 (AMG 420) is cur­rently in Phase 1 studies. BI 836908 (AMG 420) was originally licensed to Boehringer Ingelheim by Micromet before the com­pany was acquired by Amgen in 2012.

Under the provisions of the agree­ment, Amgen will work with Boehringer Ingelheim to assume re­spon­si­bil­ity­ …